P2Y12 inhibitor use predicts hematoma expansion in patients with intracerebral hemorrhage
Annals of Clinical and Translational Neurology · 2024
DOI: 10.1002/acn3.52070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2024. Verfasst von Ethan J Houskamp und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Feinberg School of Medicine, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Cerebral Hemorrhage, Purinergic P2Y Receptor Antagonists, Aspirin, Clopidogrel. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
Objective
Hematoma expansion (HE) predicts disability and death after acute intracerebral hemorrhage (ICH). Aspirin and anticoagulants have been associated with HE. We tested the hypothesis that P2Y12 inhibitors predict subsequent HE in patients. We explored laboratory measures of P2Y12 inhibition and dual antiplatelet therapy with aspirin (DAPT).
Methods
We prospectively identified patients with ICH. Platelet activity was measured with the VerifyNow‐P2Y12 assay. Hematoma volumes for initial and follow‐up CTs were calculated using a validated semi‐automated technique. HE was defined as the difference between hematoma volumes on the initial and follow‐up CT scans. Nonparametric statistics were performed with Kruskal–Wallis H , and correction for multiple comparisons performed with Dunn's test.
Results
In 194 patients, 15 (7.7%) were known to take a P2Y12 inhibitor (clopidogrel in all but one). Patients taking a P2Y12 inhibitor had more HE compared to patients not taking a P2Y12 inhibitor (3.5 [1.2–11.9] vs. 0.1 [−0.8–1.4] mL, p = 0.004). Patients taking DAPT experienced the most HE (7.2 [2.6–13.8] vs. 0.0 [−1.0–1.1] mL, p = 0.04). The use of P2Y12 inhibitors was associated with less P2Y12 activity (178 [149–203] vs. 288 [246–319] P2Y12 reaction units, p = 0.005).
Interpretation
Patients taking a P2Y12 inhibitor had more HE and less P2Y12 activity. The effect was most pronounced in patients on DAPT, suggesting a synergistic effect of P2Y12 inhibitors and aspirin with respect to HE. Acute reversal of P2Y12 inhibitors in acute ICH requires further study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Feinberg School of Medicine, Chicago, Illinois, USA.
- Department of Neurological Surgery, Feinberg School of Medicine, Chicago, Illinois, USA.
- Division of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Chicago, Illinois, USA.
- Institute for Public Health and Medicine, Feinberg School of Medicine, Chicago, Illinois, USA.
ORCID-Profile: Ethan J Houskamp, Andrew M Naidech
Förderung
- NINDS NIH HHS
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Houskamp, E. J., Liu, Y., Silva Pinheiro do Nascimento, J., Jahromi, B. S., Lindholm, P. F., Kwaan, H. C., & Naidech, A. M. (2024). P2Y12 inhibitor use predicts hematoma expansion in patients with intracerebral hemorrhage. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.52070
Vancouver
Houskamp EJ, Liu Y, Silva Pinheiro do Nascimento J, Jahromi BS, Lindholm PF, Kwaan HC, et al. P2Y12 inhibitor use predicts hematoma expansion in patients with intracerebral hemorrhage. Annals of Clinical and Translational Neurology. 2024. doi:10.1002/acn3.52070
BibTeX
@article{Houskamp2024,
author = {Houskamp, Ethan J and Liu, Yuzhe and Silva Pinheiro do Nascimento, Juliana and Jahromi, Babak S and Lindholm, Paul F and Kwaan, Hau C and Naidech, Andrew M},
title = {P2Y12 inhibitor use predicts hematoma expansion in patients with intracerebral hemorrhage},
journal = {Annals of Clinical and Translational Neurology},
year = {2024},
doi = {10.1002/acn3.52070}
}
EUVIMED